Tubercular drug delivery systems : advances in treatment of infectious diseases / Ranjita Shegokar, Yashwant Pathak, editors.
Shegokar, Ranjita.; Pathak, Yashwant.
2023
RS199.5
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Tubercular drug delivery systems : advances in treatment of infectious diseases / Ranjita Shegokar, Yashwant Pathak, editors.
ISBN 9783031141003 (electronic bk.)
3031141008 (electronic bk.)
3031140990
9783031140990
DOI https://doi.org/10.1007/978-3-031-14100-3
Imprint Cham : Springer, 2023.
Language English
Description 1 online resource (334 p.)
Other Standard Identifiers 10.1007/978-3-031-14100-3 doi
Call Number RS199.5
Dewey Decimal Classification 615/.6
Summary The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the microorganisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious diseases. Malarial drug delivery systems Tubercular drug delivery systems Viral drug delivery systems Infectious disease drug delivery systems The theme of the second book is Tuberculosis (TB). This book addresses the recent trends in drug delivery for treating TB using new formulation technologies, and the mechanism how it can prevent or delay the drug resistance. It covers current drug therapy and new drug targeting approaches focusing on innovative trend-defining technologies and drug delivery platforms. It is essential to understand the relationship between host pathogens for better treatment. Various novel and nano-formulations using promising technologies are being explored to deliver TB drugs via different administration routes at right pathological site. This book addresses the gap between new and old treatment TB modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of TB research.
Note 3.2.5 Supercritical Fluid-Based Method
Includes index.
Access Note Access limited to authorized users.
Source of Description Online resource; title from PDF title page (SpringerLink, viewed March 24, 2023).
Added Author Shegokar, Ranjita.
Pathak, Yashwant.
Available in Other Form Tubercular Drug Delivery Systems
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Intro
Preface
Volume 1: MDDS
Volume 2: TDDS
Volume 3: VDDS
Volume 4: IDDS
Contents
Global Health and Tuberculosis
Past, Present, and Future
1 What Is Tuberculosis
2 The History of the Outbreak
3 Treatments over the Time
4 Tuberculosis: World Scenario
4.1 Africa
4.2 Western Pacific/East Asia
4.3 Southern Asia
4.4 The Middle East
5 Conclusion and Future Trends
References
Tuberculosis: Cellular Understanding of Disease
1 Introduction
2 Mtb Complex
3 Initial Transmission of Mtb
4 Mechanism of Mtb-Host Interaction

4.1 Phagocytosis and Immune Cells
4.2 Inhibition of Phagolysosome Maturation
4.3 Inhibition of Phagolysosome Acidification
4.4 Inhibition of Ubiquitination
5 Classification of Tuberculosis
5.1 Pulmonary and Extrapulmonary TB
5.1.1 Pulmonary TB
5.1.2 Extrapulmonary TB
Miliary
Spine (Pott's disease)
Lymphatic (Tuberculous Lymphadenitis)
6 Organizations Involved in TB Research
7 Conclusion
References
Metal Nanoparticles in Tuberculosis
1 Introduction
2 Pathogenesis and Immunology of TB
3 Role of Macrophages

3.1 Primary Phagosome-Lysosome Fusion Prevention
3.2 Escape of M.tb into the Cytosol
3.3 Non-phagocytic Internalization of M.tb in Macrophages
4 Interaction of Metal Nanoparticles and Macrophages
5 Diagnostic Applications
5.1 Noble Metal Nanoparticles and Metal Oxide Nanoparticles-Based Diagnostics
6 Metal Nanoparticles for Targeted Treatment
7 Toxicity Aspect of Metal Nanoparticles
8 Conclusion and Future Prospective
References
Tuberculosis: Current Treatment Options and Future Scope
1 Introduction
2 Current Treatment and Drug Regimen

3 Challenges in Treatment of Tuberculosis
4 Recent Advancements in Treatment of Tuberculosis
4.1 Pharmaceutical Formulations
4.2 New Drugs or New Chemical Entities
4.3 Herbal Drugs
4.4 Recent Trials of New TB Drugs and Regimens
4.5 Vaccines
4.6 Others
5 Conclusions
References
Polymeric Nanoparticles in Tuberculosis
1 Introduction
2 Pathogenesis of Tuberculosis
3 Conventional Treatment and Its Limitation
4 Polymeric Nanoparticles
5 Polymer Used
5.1 Polysaccharide-Based Polymers
5.1.1 Chitosan Nanoparticles
5.1.2 Alginate Nanoparticles

5.1.3 Guar Gum Nanoparticles
5.2 Polypeptide and Protein-Based Polymers
5.2.1 Gelatin-Based Polymers
5.2.2 Albumin-Based Polymers
5.3 Other Synthetic Polymers
5.3.1 PLGA Nanoparticles
6 Conclusion
References
Solid Lipid Nanoparticles in Tuberculosis
1 Introduction
2 Nanotechnology in TB
3 Solid Lipid Nanoparticle
3.1 Composition of SLN
3.2 Method of Preparation of SLN
3.2.1 High-Pressure Homogenization (HPH)
3.2.2 Phase Inversion Temperature (PIT) Method
3.2.3 Microemulsion Dilution
3.2.4 Coacervation Method

Browse Subjects

Show more subjects...

Statistics

from
to
Export